MedPath

Coronary Artery Disease Severity in Newly Diagnosed Dysglycemia

Completed
Conditions
Dysglycemia
Coronary Artery Disease
Registration Number
NCT05210972
Lead Sponsor
Saud Al Babtain Cardiac Center
Brief Summary

This cohort study will measure how severe is the coronary artery disease (CAD), at time of CAD diagnosis, clinically and angiographically in the different cohorts of newly diagnosed diabetes and prediabetes versus normal glycemia patients in the study center.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
150
Inclusion Criteria
  • All adult patients with consents.
  • First time diagnosis of CAD and no prior diagnosis of diabetes milletus (DM), or prediabetes.
  • Coronary artery disease confirmed by invasive coronary angiography.
Exclusion Criteria
  1. Patients with known significant anemia, increased hemoglobin turnover, active hemoglobin drops or on erythropoietin therapy.
  2. Pregnant and post-partum patients (up to 3 months post-delivery).
  3. Patients with severe chronic renal failure (estimated glomerular filtration rate (eGFR) < 30 mL/min/1.72 m2).
  4. Patients on any medications with glucose lowering effects.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Coronary artery disease severity1 day (During the hospital admission)

To measure how severe is the CAD, at time of CAD diagnosis, clinically and angiographically in the different cohorts of newly diagnosed diabetes and prediabetes versus normal glycemia patients.

Secondary Outcome Measures
NameTimeMethod
Correlation of HbA1c to CAD severity1 day (During the hospital admission)

To correlate the level of HbA1c to the clinical and angiographic severity of CAD in the study populations

Trial Locations

Locations (1)

Saud Albatain cardiac Center

🇸🇦

Dammam, Saudi Arabia

Saud Albatain cardiac Center
🇸🇦Dammam, Saudi Arabia

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.